Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials
In this presentation, the year 1 primary results of YOSEMITE and RHINE, phase 3 pivotal trials of faricimab▼ , a bispecific Ang-2/VEGF-A inhibitor, in patients with diabetic macular edema, are presented. YOSEMITE and RHINE evaluated the efficacy, safety, and durability of faricimab▼ 6mg, administered Q8W or per personalized treatment interval with up to Q16W dosing, versus aflibercept administered Q8W.